Phathom: Why I'm Not Buying The Dip (Yet) [Seeking Alpha]
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Q4 prerelease shows VOQUEZNA revenue ramping (~15–17% Q/Q), with cost resets driving non-GAAP opex below restructuring targets. Equity raise of $130M at $16/share reduces near-term solvency risk but highlights ongoing obligations and ~11% dilution. Valuation remains stretched; PHAT is highly sensitive to execution, GTN stability, and post-2032 terminal value risk. Dragon Claws/iStock via Getty Images Introduction Despite some lingering reservations, I have become less cautious of Phathom Pharmaceuticals ( PHAT ) over time. My last analysis in September 2025 followed the achievement of VOQUEZNA's NCE exclusivity extension into 2032, which was a This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than fro
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why [Yahoo! Finance]Yahoo! Finance
- Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses [Yahoo! Finance]Yahoo! Finance
- Phathom Pharmaceuticals (PHAT) had its price target raised by Guggenheim from $20.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Phathom Pharmaceuticals (PHAT) was given a new $28.00 price target by Stifel Nicolaus.MarketBeat
PHAT
Earnings
- 2/26/26 - Beat
PHAT
Sec Filings
- 3/3/26 - Form 4
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- PHAT's page on the SEC website